SKLB1002: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71461003 |
| CHEMBL ID | 2180603 |
| MeSH ID | M0591431 |
| Synonym |
|---|
| bdbm50399536 |
| CHEMBL2180603 , |
| S7258 |
| 1225451-84-2 |
| sklb1002 |
| HY-13944 |
| CS-1807 |
| K0060 |
| c13h12n4o2s2 |
| 2-((6,7-dimethoxyquinazolin-4-yl)thio)-5-methyl-1,3,4-thiadiazole |
| AC-33004 |
| J-004821 |
| AKOS026750477 |
| EX-A319 |
| HMS3653M04 |
| sklb1002, >=98% (hplc) |
| SW220084-1 |
| mfcd27938707 |
| FT-0700126 |
| BS-14631 |
| 2-[(6,7-dimethoxyquinazolin-4-yl)thio]-5-methyl-1,3,4-thiadiazole |
| 6,7-dimethoxy-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]quinazoline |
| BCP09480 |
| sklb-1002 |
| SB19354 |
| 2-(6,7-dimethoxyquinazolin-4-yl)sulfanyl-5-methyl-1,3,4-thiadiazole |
| CCG-267711 |
| H11010 |
| NCGC00378568-07 |
| A891099 |
| AZB45184 |
| 6,7-dimethoxy-4-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]quinazoline |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0320 | 0.0000 | 0.4830 | 8.8000 | AID710632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID710558 | Antitumor activity against human HepG2 cells xenografted mouse assessed as inhibition of tumor growth at 100 mg/kg qd for 18 days | 2012 | Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24 | Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. |
| AID710619 | Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 10 uM | 2012 | Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24 | Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. |
| AID710632 | Inhibition of VEGFR2 | 2012 | Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24 | Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. |
| AID710618 | Antiangiogenic activity in zebrafish embryos assessed as inhibition of intersegmental vessel growth at 2.5 uM | 2012 | Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24 | Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. |
| AID710617 | Antitumor activity against human SW620 cells xenografted mouse assessed as inhibition of tumor growth at 100 mg/kg qd for 18 days | 2012 | Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24 | Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||